DK1121137T3 - Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter - Google Patents

Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter

Info

Publication number
DK1121137T3
DK1121137T3 DK99953196T DK99953196T DK1121137T3 DK 1121137 T3 DK1121137 T3 DK 1121137T3 DK 99953196 T DK99953196 T DK 99953196T DK 99953196 T DK99953196 T DK 99953196T DK 1121137 T3 DK1121137 T3 DK 1121137T3
Authority
DK
Denmark
Prior art keywords
adenovirus
endothelial cells
mutants
eradication
tumors
Prior art date
Application number
DK99953196T
Other languages
English (en)
Inventor
Angelica Williams
Carla Heise
Adam Sampson-Johannes
Meisa Propst
David Kirn
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK1121137T3 publication Critical patent/DK1121137T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99953196T 1998-10-26 1999-10-15 Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter DK1121137T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10570198P 1998-10-26 1998-10-26
US12130099P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
DK1121137T3 true DK1121137T3 (da) 2005-11-14

Family

ID=26802854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99953196T DK1121137T3 (da) 1998-10-26 1999-10-15 Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter

Country Status (11)

Country Link
US (1) US20020037274A1 (da)
EP (1) EP1121137B1 (da)
JP (1) JP2004517798A (da)
CN (1) CN1333689A (da)
AT (1) ATE299708T1 (da)
AU (1) AU775611B2 (da)
CA (1) CA2348634A1 (da)
DE (1) DE69926251T2 (da)
DK (1) DK1121137T3 (da)
ES (1) ES2245831T3 (da)
WO (1) WO2000024408A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175362A1 (en) * 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
ATE413807T1 (de) * 2001-01-12 2008-11-15 Sbarro Health Res Organization Hemmung der pathologischen angiogenese in vivo
US7906311B2 (en) * 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20040191761A1 (en) * 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
KR100746122B1 (ko) 2004-05-10 2007-08-03 연세대학교 산학협력단 Ｒｂ-결합능이 상실된 개선된 종양세포-특이 세포살상능을 나타내는 재조합 아데노바이러스
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
JP5650212B2 (ja) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者を選択するためのバイオマーカーおよび関連方法
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CA3096099A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152941C (en) * 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP1044280A1 (en) * 1997-12-12 2000-10-18 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS
US7078030B2 (en) * 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
WO2001036650A2 (en) * 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus

Also Published As

Publication number Publication date
US20020037274A1 (en) 2002-03-28
DE69926251T2 (de) 2006-05-24
CA2348634A1 (en) 2000-05-04
JP2004517798A (ja) 2004-06-17
EP1121137B1 (en) 2005-07-20
AU6518799A (en) 2000-05-15
ATE299708T1 (de) 2005-08-15
ES2245831T3 (es) 2006-01-16
AU775611B2 (en) 2004-08-05
WO2000024408A1 (en) 2000-05-04
CN1333689A (zh) 2002-01-30
DE69926251D1 (de) 2005-08-25
EP1121137A1 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
DK1121137T3 (da) Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter
PL343462A1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
DK1226264T3 (da) Cellelinjer og konstruktioner, der er nyttige i fremstillingen af E1-deleterede adenovirus i fravær af replikationskompetent adenovirus
WO2002098897A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2004098535A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
IS4762A (is) Samfallandi eitlaveiru genaferjukerfi og frumulínur
AU7054798A (en) Modified adenoviral fiber and target adenoviruses
DK1537146T3 (da) Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
EP1408908A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING CANCER INVASION AND ANGIOGENESIS
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
EP1545627A4 (en) TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
WO2004094614A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
EP1409653A4 (en) IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
Wang et al. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
WO2004015086A3 (en) Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker